Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15923MR)

This product GTTS-WQ15923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15923MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11530MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ8558MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ1049MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ9329MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11030MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ5253MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ8519MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ6422MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.